Page last updated: 2024-08-24

triazoles and everolimus

triazoles has been researched along with everolimus in 40 studies

Research

Studies (40)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	10 (25.00)	29.6817
2010's	30 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boulay, A; Chen, S; Evans, DB; Lane, HA; O'Reilly, T; Rudloff, J; Ye, J; Zumstein-Mecker, S	1
Lane, HA; Lebwohl, D	1
Abrial, C; Chollet, P; Curé, H; Durando, X; Leheurteur, M; Mouret-Reynier, MA; Tacca, O	1
Beeram, M; DeGraffenried, LA; Middleton, A; Russell, D; Tan, QT; Tekmal, RR	1
Awada, A; Cardoso, F; De Grève, J; Dirix, L; Fontaine, C; Piccart, M; Sotiriou, C; Steinseifer, J; Tanaka, C; Tang, P; Wouters, C; Zoellner, U	1
Collingridge, D	1
Adani, GL; Baccarani, U; Baraldo, M; Cojutti, P; Franceschi, L; Furlanut, M; Londero, A; Pea, F; Tavio, M; Viale, P	1
Fricker, J	1
Baselga, J; Bellet, M; Bianchi, G; Campone, M; Dixon, JM; Gardner, H; Greil, R; Jonat, W; Kubista, E; Lane, HA; Manikhas, A; Mayordomo, J; Molloy, B; Phillips, P; Rugo, HS; Semiglazov, V; Steinseifer, J; Stumm, M; Tokaji, E; van Dam, P	1
Abboud, I; Antoine, C; Benammar, M; Berge, M; Billaud, EM; Glotz, D; Lefeuvre, S	1
Hussar, DA	1
de Azambuja, E; Metzger-Filho, O	1
Airoud, K; Alfieri, RR; Andreis, D; Bertoni, R; Bonelli, MA; Bottini, A; Cavazzoni, A; Fumarola, C; Galetti, M; Galvani, E; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG; Tramonti, S	1
Ito, Y	1
A'Hern, R; Dowsett, M; Evans, DB; Farmer, I; Ghazoui, Z; Guest, S; Johnston, SR; Lane, HA; Martin, LA; Pancholi, S; Ribas, R; Thornhill, AM; Weigel, MT	1
De, G; Diener, M; Namjoshi, M; Wu, EQ; Xie, J; Yang, H	1
Bartlett, JM; Baselga, J; Dixon, JM; Loi, S; Michiels, S; Piccart, MJ; Sabine, VS; Sahmoud, T; Sims, AH; Singhal, SK; Sotiriou, C	1
Hou, G; Liu, J; Liu, Y; Zhang, J; Zhang, S; Zhang, X	1
Mehta, A; Tripathy, D	1
Atkins, JT; Falchook, GS; Fu, S; Hong, DS; Janku, F; Kurzrock, R; Moulder, SL; Naing, A; Piha-Paul, SA; Stephens, PJ; Tsimberidou, AM; Wheler, JJ; Yelensky, R; Zinner, R	1
Lu, XY; Xu, H; Yang, Y; Zeng, T; Zhang, ZZ	1
Kaldygul Kabakovna, S; Kuanysh Shadybayevich, N; Lewis, L; Ramil Zufarovich, A; Suriya Ertugyrovna, Y; Taylor, M	1
Brown, MP; Singhal, N; Vatandoust, S	1
Bihani, T; D'Cruz, CM; Ezell, SA; Fawell, S; Grosskurth, SE; Ladd, B; Mazzola, AM; Pietras, M; Reimer, C; Zinda, M	1
Bachelot, T; Barrios, C; de Boer, R; Di Leo, A; Janni, W; Jerusalem, G; Neven, P	1
Coleman, RL; Gershenson, DM; Jiang, Y; Johnston, T; Levenback, C; Lu, KH; Munsell, MF; Nowakowski, M; Ring, K; Slomovitz, BM; Soliman, PT; Yates, MS; Zhang, Q	1
Ito, TK; Kadariya, Y; Pei, J; Sementino, E; Tan, Y; Testa, JR	1
Atkins, JT; Janku, F; Kurzrock, R; Moulder, SL; Stephens, PJ; Wheler, JJ; Yelensky, R	1
Bozhok, AA; Dashyan, GA; Komyakhov, AV; Lalak, IA; Manikhas, AG; Paltuev, RM; Petrenko, OL; Semiglazov, VF; Semiglazov, VV; Semiglazova, TY	1
Johnston, SR	1
Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I	1
Bregni, G; de Braud, F; Di Cosimo, S; Zanardi, E	1
Batson, S; Jones, N; Livings, C; Telford, C	1
Aboukameel, A; Azmi, AS; Baloglu, E; Bhutani, D; Carlson, R; Elloul, S; Kauffman, M; Mohammad, RM; Muqbil, I; Senapedis, W; Shacham, S; Zonder, J	1
Niraula, S; Ocana, A	1
Block, MS; Colon-Otero, G; Copland, JA; Dinh, TA; Foster, NR; Haluska, P; Hou, X; Jatoi, A; Robertson, MW; Wahner-Hendrickson, AE; Weroha, SJ	1
Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D	1
Assi, T; El Rassy, E; Kattan, J; Kourie, HR; Moussa, T	1
Cao, M; Deng, H; Liu, J; Rao, N; Wu, W; Yang, Y; You, N	1
Fan, P; Fang, R; Jin, X; Liu, T; Lu, X; Zeng, L; Zhang, B	1

Reviews

9 review(s) available for triazoles and everolimus

Article	Year
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program. Seminars in oncology, 2006, Volume: 33, Issue:2 Suppl 7 Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Forecasting; Humans; Immunosuppressive Agents; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Sirolimus; Triazoles	2006
[Progress of molecularly targeted therapy for breast cancer]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:4 Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles	2012
Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:1 Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles	2014
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer. Cancer treatment reviews, 2015, Volume: 41, Issue:2 Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Nitriles; Patient Selection; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Failure; Treatment Outcome; Triazoles	2015
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways. Journal of the National Cancer Institute, 2015, Volume: 107, Issue:10 Topics: Adult; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Middle Aged; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Research Design; Signal Transduction; Triazoles	2015
Better Together: Targeted Combination Therapies in Breast Cancer. Seminars in oncology, 2015, Volume: 42, Issue:6 Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles	2015
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy. Clinical breast cancer, 2016, Volume: 16, Issue:3 Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles	2016
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy. Cancer treatment reviews, 2016, Volume: 50 Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles	2016
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis. Current medical research and opinion, 2017, Volume: 33, Issue:8 Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Triazoles	2017

Trials

9 trial(s) available for triazoles and everolimus

Article	Year
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:1 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Drug Interactions; Everolimus; Feasibility Studies; Female; Humans; Immunosuppressive Agents; Letrozole; Male; Middle Aged; Nitriles; Sirolimus; Treatment Outcome; Triazoles	2008
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-01, Volume: 27, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Cyclin D1; Double-Blind Method; Europe; Everolimus; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Mutation; Neoadjuvant Therapy; Nitriles; Palpation; Phosphatidylinositol 3-Kinases; Phosphorylation; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Ribosomal Protein S6 Kinases; Sirolimus; Time Factors; Treatment Outcome; Triazoles; United States	2009
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PloS one, 2013, Volume: 8, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Everolimus; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Letrozole; Middle Aged; Mutation; Nitriles; Phosphatidylinositol 3-Kinases; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Triazoles	2013
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget, 2014, May-30, Volume: 5, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Genital Neoplasms, Female; Humans; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles; Young Adult	2014
Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity. Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:2 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Humans; Letrozole; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Nitriles; Organoplatinum Compounds; Sirolimus; Smoking; Triazoles	2015
Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-10, Volume: 33, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bayes Theorem; beta Catenin; Biomarkers, Tumor; Cohort Studies; Disease-Free Survival; DNA Mutational Analysis; Endometrial Neoplasms; Endometriosis; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Immunosuppressive Agents; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles	2015
[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER]. Voprosy onkologii, 2015, Volume: 61, Issue:3 Topics: Adult; Aged; Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Everolimus; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Triazoles	2015
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecologic oncology, 2017, Volume: 146, Issue:1 Topics: Administration, Oral; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Disease-Free Survival; Everolimus; Female; Humans; Letrozole; Mice; Mice, SCID; Middle Aged; Neoplasm Grading; Nitriles; Ovarian Neoplasms; Receptors, Estrogen; Triazoles; Xenograft Model Antitumor Assays	2017
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial. Trials, 2017, Oct-25, Volume: 18, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; China; Clinical Protocols; Cyclophosphamide; Epirubicin; Everolimus; Feasibility Studies; Female; Fluorouracil; Humans; Letrozole; Lymphatic Metastasis; Neoadjuvant Therapy; Nitriles; Pilot Projects; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Treatment Outcome; Triazoles; Tumor Burden	2017

Other Studies

22 other study(ies) available for triazoles and everolimus

Article	Year
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jul-15, Volume: 11, Issue:14 Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Cell Proliferation; Cell Survival; Drug Interactions; Estrogens; Everolimus; Female; Humans; Immunosuppressive Agents; Letrozole; Nitriles; Protein Kinases; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured	2005
Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clinical breast cancer, 2006, Volume: 7, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Nitriles; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles	2006
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:8 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Flow Cytometry; Fulvestrant; Humans; Letrozole; Nitriles; Protein Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Triazoles	2007
San Antonio Breast Cancer Symposium. The Lancet. Oncology, 2008, Volume: 9, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles	2008
Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. The Annals of pharmacotherapy, 2008, Volume: 42, Issue:11 Topics: Aged; Antifungal Agents; Aspergillosis; Drug Interactions; Everolimus; Fatal Outcome; Fluconazole; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Pyrimidines; Sirolimus; Triazoles; Voriconazole	2008
San Antonio Breast Cancer Symposium. The Lancet. Oncology, 2009, Volume: 10, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid	2009
Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient. Clinical drug investigation, 2009, Volume: 29, Issue:7 Topics: Antifungal Agents; Aspergillosis; Cytochrome P-450 CYP3A; Drug Interactions; Drug Monitoring; Everolimus; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pyrimidines; Sirolimus; Triazoles; Voriconazole	2009
New Drugs2010, PART 1. Nursing, 2010, Volume: 40, Issue:2 Topics: Acetamides; Antibodies, Monoclonal; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Azepines; Benzazepines; Benzhydryl Compounds; Benzyl Alcohol; Benzylamines; Cyclams; Cyclopropanes; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Ethanolamines; Everolimus; Febuxostat; Fluorenes; Fluoroquinolones; Gout Suppressants; Heterocyclic Compounds; Humans; Immunosuppressive Agents; Indoles; Lacosamide; Milnacipran; Oligopeptides; Phenols; Selective Serotonin Reuptake Inhibitors; Sirolimus; Tapentadol; Thiazoles; Tolvaptan; Triazoles	2010
Neoadjuvant chemotherapy and targeted therapies: a promising strategy. Journal of the National Cancer Institute. Monographs, 2011, Volume: 2011, Issue:43 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles	2011
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer letters, 2012, Oct-01, Volume: 323, Issue:1 Topics: Aged; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imidazoles; Immunosuppressive Agents; Letrozole; Neoadjuvant Therapy; Nitriles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles	2012
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo. Breast cancer research : BCR, 2012, Oct-17, Volume: 14, Issue:5 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Nucleolus; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays	2012
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. Journal of medical economics, 2013, Volume: 16, Issue:2 Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Everolimus; Female; Health Care Costs; Humans; Letrozole; Middle Aged; Nitriles; Receptor, ErbB-2; Severity of Illness Index; Sirolimus; Treatment Failure; Triazoles; United States	2013
Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:2 Topics: Animals; Apoptosis; Aromatase; Breast Neoplasms; Cell Proliferation; Drug Synergism; Elafin; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Mice; Nitriles; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays	2014
Synergistic in vitro anti-tumor effect of letrozole and everolimus on human endometrial carcinoma Ishikawa cells. European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:16 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Endometrial Neoplasms; Everolimus; Female; Humans; Letrozole; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoproteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sirolimus; TOR Serine-Threonine Kinases; Triazoles	2014
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan. Journal of medical economics, 2015, Volume: 18, Issue:3 Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Everolimus; Female; Humans; Kazakhstan; Letrozole; Nitriles; Postmenopause; Receptor, ErbB-2; Triazoles	2015
Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. Oncotarget, 2015, Feb-10, Volume: 6, Issue:4 Topics: Animals; Antineoplastic Agents; Azepines; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; MCF-7 Cells; Mice, Nude; Nuclear Proteins; Proto-Oncogene Proteins c-myc; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays	2015
Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice. Cancer biology & therapy, 2015, Volume: 16, Issue:4 Topics: Animals; Apoptosis; Azepines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Everolimus; Homeodomain Proteins; Imidazoles; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Mice; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Quinolines; Signal Transduction; Thiazoles; Transcription, Genetic; Triazoles; Vincristine	2015
Multiple gene aberrations and breast cancer: lessons from super-responders. BMC cancer, 2015, May-29, Volume: 15 Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Everolimus; Female; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Proteins; Nitriles; Phosphatidylinositol 3-Kinases; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles	2015
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line. Oncology, 2015, Volume: 89, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles	2015
Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Cancer letters, 2016, 12-28, Volume: 383, Issue:2 Topics: Acrylamides; Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Everolimus; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Lymphoma, Non-Hodgkin; Mice, Inbred ICR; Mice, SCID; Oxadiazoles; Prednisone; Protein Kinase Inhibitors; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Time Factors; TOR Serine-Threonine Kinases; Transcription Factor RelA; Triazoles; Tumor Burden; Vincristine; Xenograft Model Antitumor Assays	2016
Response of an ovarian granulosa cell tumor with everolimus and exemestane after initial response to letrozole. Anti-cancer drugs, 2017, Volume: 28, Issue:8 Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Granulosa Cell Tumor; Humans; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Triazoles	2017
PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer. Journal of experimental & clinical cancer research : CR, 2019, Nov-12, Volume: 38, Issue:1 Topics: Animals; Antineoplastic Agents; Azepines; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cytoprotection; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phthalazines; Piperazines; Prognosis; Proteins; Proto-Oncogene Proteins c-myc; RNA-Binding Proteins; Transfection; Triazoles	2019